NCT00627419

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

A Phase 2, Open-Label, Single-Arm, Multicenter Study Evaluating the Safety and Antitumor Activity of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90 (HSP90), in Patients With Metastatic Melanoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Infinity Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.

Detailed description

To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma and to assessment of antitumor activity is the 6-month progression-free rate.

Conditions

• Metastatic Melanoma

Interventions

Type	Name	Description
DRUG	IPI-504	Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.

Timeline

• Start date: 2008-02-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2008-03-03
• Last updated: 2012-12-10

Locations

17 sites across 1 country: United States